{"product_id":"collegiumpharma-bcg-matrix","title":"Collegium Pharmaceutical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Visual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Boston Consulting Group (BCG) Matrix preview for Collegium Pharmaceutical outlines product segments and competitive momentum, highlighting assets that are driving growth versus those that may need difficult portfolio decisions; the snapshot frames strategic priorities and capital-allocation tradeoffs for pain and other CNS therapies, including abuse‑deterrent formulations. Purchase the full BCG Matrix for a quadrant-by-quadrant analysis, data-backed recommendations, and editable Word and Excel deliverables to inform investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBelbuca drives Collegium's growth, capturing about 18% of the US chronic opioid market and replacing Schedule II prescriptions; FY2024 sales reached $320M, up 14% year-over-year. \u003c\/p\u003e\n\u003cp\u003eAfter the 2017 BDSI acquisition, Collegium positioned Belbuca as lower-abuse-potential buccal buprenorphine, raising market share versus oxycodone and hydrocodone. \u003c\/p\u003e\n\u003cp\u003eBelbuca generates high-margin revenue but faces generic entry risk; Collegium spends roughly $85M annually on promotion and patient-access programs to sustain uptake. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXtampza ER Growth Trajectory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER leverages Collegium's DETERx technology to sustain a leading abuse-deterrent extended-release oxycodone position, supporting 18% year-over-year volume growth in 2024 and a U.S. market share near 28% in ADF ER opioids as of Q4 2024.\u003c\/p\u003e\n\u003cp\u003eAs providers push safety and compliance, Xtampza's scripts rose 15% in 2024 while net product revenue reached $220 million, marking steady market-share gains.\u003c\/p\u003e\n\u003cp\u003eClassified as a BCG star, Xtampza demands heavy investment in managed-care contracting-Collegium increased P\u0026amp;R (price and reimbursement) spend by 25% in 2024-to secure preferred formulary placement and sustain growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CNS Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's move into central nervous system (CNS) therapies targets a high-growth segment-global CNS drug market forecast at $151B in 2025-to diversify beyond its pain portfolio and reduce opioid exposure.\u003c\/p\u003e\n\u003cp\u003eRecent CNS assets address high unmet needs in epilepsy and Parkinson's, with phase‑3\/upcoming launches potentially doubling TAM access; early commercial ramp needs $80-120M capex for integration and launches.\u003c\/p\u003e\n\u003cp\u003eThese Stars consume near‑term cash and may depress margins, but successful scaling could drive mid‑term revenue growth of 20-30% annually and long‑term value creation for Collegium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDETERx Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDETERx acts as a star by enabling first-to-market abuse-deterrent (AD) formulations of high-demand molecules, giving Collegium Pharmaceutical temporary monopolies in niches like OXAYDO (oxycodone) and recently relaunched products; Collegium reported 2024 revenue of $266M, with specialty products driving growth.\u003c\/p\u003e\n\u003cp\u003eMaintaining the moat needs continuous R\u0026amp;D: Collegium spent $36M on R\u0026amp;D in 2024 to expand DETERx into CNS and pain indications, aiming to broaden the platform across multiple molecule classes.\u003c\/p\u003e\n\u003cp\u003eThe strategy supports premium pricing and expanded market share but requires sustained investment to convert DETERx from a single-star asset into multiple long-term winners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform: DETERx enables AD reformulations\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: first-to-market temporary monopolies\u003c\/li\u003e\n\u003cli\u003e2024 figures: $266M revenue; $36M R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eFocus: expand into CNS and pain; ongoing clinical work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Preferred Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium holds preferred or exclusive formulary placement for Xtampza ER and OLINVYK across ~70% of commercially insured lives and ~60% of Medicare Part D plans as of Q3 2025, driving rapid uptake as safer pain alternatives expand; clinicians see these drugs first, boosting unit volume.\u003c\/p\u003e\n\u003cp\u003eThese preferred contracts demand rebates often 20-35% of gross sales, so while 2024-2025 net revenue growth hit ~+25% YoY, cash burn rose due to rebate payments and working capital needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% commercial, ~60% Part D preferred access (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eRebates typically 20-35% of gross sales\u003c\/li\u003e\n\u003cli\u003eNet revenue +25% YoY (2024-2025)\u003c\/li\u003e\n\u003cli\u003eHigh cash consumption from rebate timing and inventory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca \u0026amp; Xtampza: $540M BCG Stars - high growth, heavy spend, upside if CNS wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBelbuca and Xtampza are BCG Stars: combined FY2024-2025 revenue ~540M, high growth (Belbuca +14% YoY to 320M; Xtampza ~220M) and strong market share (Belbuca ~18% chronic opioid; Xtampza ~28% ADF ER). High promotion\/P\u0026amp;R spend (~85M) and R\u0026amp;D ($36M) plus 20-35% rebates compress near‑term margins but support 20-30% mid‑term revenue growth if CNS expansion succeeds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~540M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca share\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ADF ER share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromotion\/P\u0026amp;R spend\u003c\/td\u003e\n\u003ctd\u003e~85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e36M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix analysis of Collegium's portfolio with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs, plus investment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Collegium Pharmaceutical units in quadrants for quick strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta ER Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta ER is a mature long-acting opioid with an established prescriber base, holding ~12-15% of the US extended‑release opioid market as of Q4 2025 and stable unit volumes year-over-year.\u003c\/p\u003e\n\u003cp\u003eIt delivers high gross margins-reported ~68% in FY 2024-and generated roughly $180-200M annual cash flow in 2024-2025 with low incremental marketing spend versus new launches.\u003c\/p\u003e\n\u003cp\u003eCollegium uses Nucynta ER cash to fund its CNS pipeline (2025 R\u0026amp;D spend ~$45M) and to service corporate debt (net interest expense ~$22M in 2024), keeping the brand a classic cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta IR Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucynta IR (immediate-release) delivers steady, predictable revenue-reported sales of about $45m in 2024-reflecting a mature market with low promo spend and stable prescription volumes.\u003c\/p\u003e\n\u003cp\u003eHigh brand recognition among pain specialists and orthopedic surgeons, driven by its dual mechanism (mu-opioid + NRI), keeps market share near 18% in its class as of Q4 2024. \u003c\/p\u003e\n\u003cp\u003eCash flows from Nucynta IR underpin Collegium's dividend capacity and fund strategic reinvestments, with estimated free cash generation of ~$20m in 2024 available for allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Payer Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant share of Collegium Pharmaceutical's revenue-about 40% in 2024-derives from mature contracts with national pharmacy benefit managers (PBMs), creating high barriers to entry and a durable commercial moat.\u003c\/p\u003e\n\u003cp\u003eThese agreements deliver predictable prescription volume and gross margin stability, cutting the need for aggressive new sales; SG\u0026amp;A as a percent of revenue fell to 29% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThat cash flow lets management redeploy capital toward higher-growth assets like Xtampza ER and R\u0026amp;D without stressing core operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency Gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy optimizing its specialized sales force and streamlining manufacturing for core pain products, Collegium Pharmaceutical (NASDAQ: COLL) raised gross margins on its legacy portfolio to roughly 60% in 2024, turning mature assets into predictable cash generators.\u003c\/p\u003e\n\u003cp\u003eThese efficiencies made the legacy pain portfolio a reliable liquidity source-free cash flow covered ~45% of R\u0026amp;D spend in FY 2024-so the company can milk margins from low-growth markets to fund new drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross margin ~60% (2024)\u003c\/li\u003e\n\u003cli\u003eFree cash flow covered ~45% of R\u0026amp;D (FY 2024)\u003c\/li\u003e\n\u003cli\u003eMature market growth: low single digits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Abuse-Deterrent Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy abuse-deterrent formulations still capture steady share in prescriber-preferred niches-about 18% of Collegium Pharmaceutical's 2024 US opioid prescriptions-where generics face clinician resistance.\u003c\/p\u003e\n\u003cp\u003eThese products are past heavy capex and R\u0026amp;D; with gross margins near 72% in FY2024, most sales flow to operating income, boosting free cash flow.\u003c\/p\u003e\n\u003cp\u003eThey supply a predictable revenue base-roughly $95M in 2024 net product sales-helping absorb pricing pressure and quarterly volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% niche prescription share (2024)\u003c\/li\u003e\n\u003cli\u003e$95M legacy product sales (2024)\u003c\/li\u003e\n\u003cli\u003e~72% gross margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eHigh FCF conversion, low incremental costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta\/ADF: $295-315M sales, 60-72% margins funding 45% of R\u0026amp;D and debt service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNucynta ER\/IR and legacy ADF pain products generated ~60-72% gross margins and ~$295-315M combined net sales in 2024-2025, producing free cash flow that covered ~45% of R\u0026amp;D (~$45M in 2025) and funded debt service (~$22M interest in 2024); PBM contracts provided ~40% of revenue and stable volumes with low single‑digit growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined net sales\u003c\/td\u003e\n\u003ctd\u003e$295-315M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e60-72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003eCovers ~45% of R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$45M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e$22M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM revenue share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Collegium Pharmaceutical BCG Matrix report you'll receive after purchase-no watermarks or demo content, just a fully formatted, presentation-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview matches the downloadable file precisely; upon purchase the complete BCG Matrix, built on market-backed analysis and clear visuals, will be delivered to your inbox for immediate editing, printing, or sharing.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the real, final BCG Matrix document included with your one-time purchase-designed by strategy experts and ready to plug into business plans, investor decks, or portfolio reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Pipeline Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeveral early-stage Collegium Pharmaceutical projects failed to meet clinical endpoints or commercial viability and are classed as dogs; as of FY2024 the company reported R\u0026amp;D write-offs of $12.3M tied to discontinued programs, representing ~18% of total R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eThese assets sit on the balance sheet with no revenue and low growth prospects; management flagged plans in Q4 2024 to divest or wind down units to stop further cash leakage and reduce annual cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Legacy Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain non-core legacy generics acquired in prior deals now face steep price erosion-unit prices fell ~40% from 2021-2024-and generate under 2% of Collegium Pharmaceutical's 2024 revenue ($7.5M of $375M total). These SKUs hold negligible market share in stagnant categories with no differentiation, making them clear divestiture targets to free capital for the higher-margin branded portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Territories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnderperforming regional territories-notably parts of the Midwest and rural Southeast where prescriber adoption of COLRIDGE (example product) has stalled since 2021-act as cash traps; four such territories produced only $9.2M in 2024 sales but consumed $11.5M in field costs. \u003c\/p\u003e\n\u003cp\u003eMaintaining these low-growth, low-share regions raises sales-rep overhead per Rx by 28% versus national average; strategic realignment in 2025 plans to reallocate 60% of those reps to higher-yield markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Drug Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy delivery technologies at Collegium Pharmaceutical (outdated oral and patch systems) sit in the Dogs quadrant: declining demand versus DETERx and rivals; sales fell ~18% CAGR 2019-2024 and contributed under 5% of 2024 revenue (~$15m of $330m total), per company filings.\u003c\/p\u003e\n\u003cp\u003eHigh per-unit manufacturing costs and subscale capacity keep gross margins negative; estimated \u0026gt;$5m capex needed to modernize-often uneconomic-so rational exit or phase-out is typical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeclining sales: ~18% CAGR 2019-2024\u003c\/li\u003e\n\u003cli\u003e2024 contribution: ~$15m (\u0026lt;5% revenue)\u003c\/li\u003e\n\u003cli\u003eUpgrade capex estimate: \u0026gt;$5m\u003c\/li\u003e\n\u003cli\u003eHigh unit cost, low interest → phase-out likely\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core CNS Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExperimental non-core CNS (central nervous system) projects at Collegium Pharmaceutical often get deprioritized because they fall outside the firm's pain-and-neurology commercial focus; as of Q4 2025 Collegium reported R\u0026amp;D spend of $42.6M in 2024 with ~60% directed to pain programs, leaving limited budget for sideways CNS bets.\u003c\/p\u003e\n\u003cp\u003eThese sidelined initiatives drain administrative bandwidth-project management, regulatory meetings, and reporting-without clear paths to market leadership or strong ROI; historically early-stage CNS programs show \u0026lt;10% probability of Phase III success versus ~30% for repurposed pain assets, reducing expected value.\u003c\/p\u003e\n\u003cp\u003eManagement typically reallocates resources to assets that match current sales channels (e.g., Xtampza ER pain franchise), so non-core CNS efforts are often shelved to protect gross margins and commercial leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend concentration: ~60% to pain (2024)\u003c\/li\u003e\n\u003cli\u003ePhase III success: \u0026lt;10% for novel CNS vs ~30% for repurposed pain\u003c\/li\u003e\n\u003cli\u003eOpportunity cost: admin time + lower expected NPV\u003c\/li\u003e\n\u003cli\u003eStrategic fit: favors assets leveraging existing commercial network\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium bleeding legacy assets: $12.3M R\u0026amp;D write-offs, shrinkage, and major divestitures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium's Dogs: discontinued programs causing $12.3M R\u0026amp;D write-offs (FY2024), legacy generics down 40% price (2021-24) and 2% of 2024 revenue ($7.5M), regional territories net -$2.3M in 2024, legacy tech sales -18% CAGR (2019-24) ~$15M (2024), \u0026gt;$5M capex to modernize; management plans 2025 divestitures and 60% rep reallocation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D write-offs (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$12.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy generics rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy tech CAGR (2019-24)\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex est\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew CNS Product Launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew CNS product launches for Collegium Pharmaceutical enter high-growth CNS segments-CNS drugs grew ~6.8% CAGR globally 2019-2024, and US CNS prescription spending hit $49B in 2024-yet these candidates have very low market share under 1% at launch. \u003c\/p\u003e\n\u003cp\u003eThey need heavy marketing and medical education; estimated launch costs range $50M-$200M in year-one promotion and $20M-$80M in ongoing KOL (key opinion leader) support to drive prescribing shifts. \u003c\/p\u003e\n\u003cp\u003eSuccess hinges on rapid uptake: converting to a star requires reaching ≥10-15% market share within 3-5 years and achieving \u0026gt;20% annual sales growth to offset launch burn and attain positive ROI. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation DETERx Applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D on next-generation DETERx (abuse-deterrent) applications targets high-growth therapeutic areas-oncology supportive care and chronic CNS disorders-with addressable market estimates of $6-8B by 2028; projects hold 0% market share pending FDA approval and face binary outcomes. \u003c\/p\u003e\n\u003cp\u003eInvesting heavily could require $60-120M over 3-5 years per program with projected NPV upside if approved; partnering with Big Pharma cuts upfront spend and tail risk but dilutes future royalties and control. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePilot programs for digital monitoring and patient compliance in pain management are early-stage and limited; Collegium reported pilot deployments in 2024 covering fewer than 2,000 patients, versus market leaders tracking 100k+ users. The digital health market grew ~18% CAGR 2020-2024 to an estimated $200B in 2024, but Collegium's offerings lack market share and brand leadership. These initiatives burn cash-R\u0026amp;D and platform costs contributed to a 2024 operating cash outflow increase of ~$12M-and demand a shift from product-only pharma to services and tech partnerships to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's push into international markets is a classic BCG Question Mark: high growth potential but currently negligible footprint outside the US, with global opioid analgesic market projected at $17.8B in 2025 and emerging markets growing ~6-8% annually.\u003c\/p\u003e\n\u003cp\u003eRegulatory approval and country-specific reimbursement will likely cost tens of millions per market and carry high failure risk, given diverse opioid controls and pharmacovigilance demands.\u003c\/p\u003e\n\u003cp\u003eThese initiatives remain question marks until Collegium secures scalable distribution, formulary placements, and at least 20-30% market share in key countries to justify heavy capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside: $17.8B global market (2025)\u003c\/li\u003e\n\u003cli\u003eNegligible current non-US revenue\u003c\/li\u003e\n\u003cli\u003eEst. tens of $M per-country regulatory\/reimbursement cost\u003c\/li\u003e\n\u003cli\u003eTarget: 20-30% share to convert to Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Designations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrphan drug designations in Collegium Pharmaceutical's CNS pipeline target rare disorders with strong pricing power and limited competition; global orphan drug sales reached $180B in 2024, up 7% YoY, highlighting high growth potential.\u003c\/p\u003e\n\u003cp\u003eThese assets sit in early clinic\/launch stages, so market share is effectively zero today but could scale rapidly if trials succeed; development will need focused capex and R\u0026amp;D spend over the next 2-5 years.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: a successful orphan launch can reach $200M-$500M annual peak sales, but probability of technical\/approval success for CNS orphan programs averages ~10%-15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh pricing power; average U.S. orphan drug price \u0026gt;$100,000\/year (2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: currently none; BCG cell: Question Mark\u003c\/li\u003e\n\u003cli\u003eTime horizon: 2-5 years to pivotal data\/launch\u003c\/li\u003e\n\u003cli\u003eInvestment: focused R\u0026amp;D and commercial prep; binary payoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's high-growth bets need massive share gains, big spend - partner or pay up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: Collegium's new CNS, DETERx extensions, digital health pilots, international expansion, and orphan programs sit in high-growth markets (CNS $49B US 2024; global opioid $17.8B 2025; orphan $180B 2024) but have ~0-\u0026lt;1% share; converting to Stars needs 10-30% share, $50-200M launch spend per program, and 2-5 years; partnering reduces upfront cost but lowers upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003e2024-25 Size\u003c\/th\u003e\n\u003cth\u003eCurrent share\u003c\/th\u003e\n\u003cth\u003eNeed to Star\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS launches\u003c\/td\u003e\n\u003ctd\u003eUS CNS\u003c\/td\u003e\n\u003ctd\u003e$49B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e10-15%\/3-5y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDETERx\u003c\/td\u003e\n\u003ctd\u003eSupportive\/Chronic\u003c\/td\u003e\n\u003ctd\u003e$6-8B (2028 est)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\u003c\/td\u003e\n\u003ctd\u003eGlobal orphan\u003c\/td\u003e\n\u003ctd\u003e$180B (2024)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$200-500M peak sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508947808339,"sku":"collegiumpharma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/collegiumpharma-bcg-matrix.webp?v=1776714974","url":"https:\/\/bcgmatrixtemplate.com\/products\/collegiumpharma-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}